Orchid Pharma Limited (NSE:ORCHPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 39.41B +0.2% |
| Revenue (ttm) | 8.11B -8.2% |
| Net Income | 205.47M -79.4% |
| EPS | 4.05 -79.4% |
| Shares Out | 50.72M |
| PE Ratio | 191.88 |
| Forward PE | 24.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 88,421 |
| Open | 812.45 |
| Previous Close | 792.50 |
| Day's Range | 770.30 - 829.00 |
| 52-Week Range | 480.00 - 899.00 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 976.00 (+25.6%) |
| Earnings Date | May 25, 2026 |
About Orchid Pharma
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly... [Read more]
Financial Performance
In fiscal year 2026, Orchid Pharma's revenue was 8.47 billion, a decrease of -8.18% compared to the previous year's 9.22 billion. Earnings were 205.47 million, a decrease of -79.38%.
Financial StatementsNews
Orchid Pharma Transcript: Q4 25/26
FY 2026 saw stable Q4 revenue and EBITDA, but full-year results declined due to industry-wide pricing pressures. Strategic initiatives, including the Dhanuka merger and new product launches, position the company for recovery and growth, with 10–15% sales growth targeted for FY 2027.
Orchid Pharma Quarterly report: Q4 2026
Orchid Pharma has published its Q4 2026 quarterly earnings report on May 26, 2026.
Orchid Pharma Slides: Q4 2026
Orchid Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 26, 2026.
Pharma Stocks Today, May 13: Wockhardt rises 1.97%, Orchid Pharma falls 1.79%, Biocon gains 1.38%
Indian pharmaceutical stocks showed a mixed trend on May 13 2026 during the early morning trading session. The BSE Healthcare index remained nearly flat, rising marginally by 0.04% to 46,087.93.…
Pharma sector stocks fall today, May 12: Orchid Pharma falls 3.74%, J.B. Chemicals down 2.67%, Biocon rises 0.79%
Indian pharmaceutical stocks opened lower on May 12 2026. The BSE Healthcare index declined 0.74% to 46,474.08 in the early morning trade. The broader market also remained weak with the…
Pharma sector stocks fall today, May 12: Orchid Pharma falls 3.74%, J.B. Chemicals down 2.67%, Torrent Pharma drops 2%
Indian pharmaceutical stocks opened lower on May 12 2026. The BSE Healthcare index declined 0.74% to 46,474.08 in the early morning trade. The broader market also remained weak with the…
Pharma sector stocks today, April 29: Orchid Pharma surges 3.35%, Torrent Pharma up 1.78%, Glenmark Pharma rises 1.72%
The Indian pharmaceutical sector opened on a broadly positive note on April 29, 2026. Of the 24 pharma stocks tracked, the majority are trading in the green in early trade…
Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77%
Shares of pharmaceutical sector companies traded broadly higher on April 23, 2026, with Dr. Reddy's Laboratories, Strides Pharma Science, Orchid Pharma, and Glenmark Pharma among the standout gainers,...
Pharma sector stocks surge today, April 15: Indoco Remedies up 5%, Orchid Pharma gains 4.04%, Dr. Reddy's falls 1.64%
Indian pharmaceutical sector stocks traded higher in early morning trade on Tuesday, April 15, 2026, with most counters advancing while Dr. Reddy's Laboratories remained an outlier on the downside. Am...
Orchid Pharma Transcript: Q3 25/26
Q3 FY26 saw a 5% YoY sales decline and margin compression due to global antibiotic market stress and lower regulated market sales. Cost optimization and R&D investments continue, while new launches and the 7-ACA project are expected to drive future growth.
Orchid Pharma Quarterly report: Q3 2026
Orchid Pharma has published its Q3 2026 quarterly earnings report on February 12, 2026.
Orchid Pharma Slides: Q3 2026
Orchid Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 12, 2026.
Orchid Pharma shares slip over 3% as Q3 EBITDA falls 94.2% YoY to Rs 1.5 crore
Orchid Pharma shares slipped more than 3% in early trade on February 12 (IST) after the company reported a sharp...
Orchid Pharma Transcript: Q2 25/26
Q2 FY26 saw a 13% YoY sales decline but sequential improvement, with gross margin compression due to weak pricing and inventory liquidation. Strategic acquisition of emmetazobactam rights positions for future growth, while the antibiotics market remains under pressure.
Orchid Pharma Quarterly report: Q2 2026
Orchid Pharma has published its Q2 2026 quarterly earnings report on November 11, 2025.
Orchid Pharma Slides: Q2 2026
Orchid Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 11, 2025.
Orchid Pharma Transcript: Q1 25/26
Q1 FY26 saw a 29% sales decline due to a global antibiotics slowdown, but gross margins were preserved at 42%. The company acquired global rights to Enmetazobactam, expects no debt for the deal, and is focused on disciplined execution and margin protection amid ongoing market contraction.
Orchid Pharma Quarterly report: Q1 2026
Orchid Pharma has published its Q1 2026 quarterly earnings report on August 12, 2025.
Orchid Pharma Slides: Q1 2026
Orchid Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 12, 2025.
Top stocks to buy today: Stock recommendations for July 16, 2025 - check list
Stock market recommendations: Anand Rathi Shares suggests buying Tilak Nagar Industries, Orchid Pharma, and ITC. Tilak Nagar Industries shows range breakout with volume support. Orchid Pharma indicate...
Orchid Pharma shares drop nearly 5% as Q4 net profit falls 32.4% YoY to Rs 22.3 crore
Orchid Pharma witnessed a sharp decline in its stock price, falling nearly 5% following the release of its fourth-quarter results for FY25. As of 10:11 AM, the shares were trading 4.98% lower at Rs 70...
Orchid Pharma Transcript: Q4 24/25
Q4 and FY2024 saw double-digit sales and EBITDA growth, but ongoing pricing pressure and project delays are expected to mute FY2026 performance. The AMS division is building scale, Enmetazobactam is outperforming in India, and the Dhanuka merger is set to strengthen the business.
Orchid Pharma Annual report: Q4 2025
Orchid Pharma has published its Q4 2025 annual report on May 26, 2025.
Orchid Pharma Slides: Q4 2025
Orchid Pharma has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on May 26, 2025.
Orchid Pharma shares surge 4.4% after successful USFDA inspection at Alathur API facility
Orchid Pharma Ltd. saw a 4% jump in its stock price following the successful completion of a surprise inspection by the United States Food and Drug Administration (USFDA) at its Active Pharmaceutical ...